Clinical Trial: Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Randomised, Open-label, Parallel-group Study to Evaluate the Efficacy and Safety of ACTIQ (Oral Transmucosal Fentanyl Citrate) Titrated According to 2 Regimens in Patients With Cancer and
Brief Summary: The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a successful dose of ACTIQ treatment more quickly. The successful ACTIQ dose provides a satisfactory combination of efficacy and tolerability after a single administration, as assessed by the patient.
Detailed Summary:
Sponsor: Cephalon
Current Primary Outcome: to determine if ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Teva Pharmaceutical Industries
Dates:
Date Received: October 7, 2005
Date Started: June 2004
Date Completion:
Last Updated: January 28, 2013
Last Verified: October 2005